Asahi Glass Company, Limited

The Green Cross Corporation

Santen Pharmaceutical Co., Ltd.

Mitsubishi Pharma Corporation

Beijing Tide Pharmaceutical Co., Ltd.

Ltt Bio-Pharma Co., Ltd.

Yoshitomi Morizawa

Hiroshi Yamamoto

Yasushi Matsumura

Takashi Nakano

Takashi Okazoe

Yoshihisa Inoue

Norifumi Nakamura

Arata Yasuda

Hajime Ebisu

Jun Sasaki

Nobuaki Mori

Naomichi Ishida

Mayumi Makino

Tomoyuki Fujita

Naoko Shirota

Yoshiki Hamatani

Tadashi Nakajima

Eiichi Shirasawa

Hideshi Sasakura

Masaaki Kageyama

Koichi Murata

Kazuya Oharu

Atsushi Watakabe

Koji Ikawa

Kimiaki Kashiwagi

Osamu Yokokoji

Shu-zhong Wang

Ken Iruya

Toshihiko Kaminuma

Takehiko Sakamoto

Kuniko Okano

Hideo Nomoto

Hisao Hori

Shuzhong Wang

Tomoko Ito

Toshiaki Nakayama

Maki Murahashi

Kana Ishikawa

Tetsuya Yanoshita

Yuuichi Aoki

Masahiro Urushihara

To provide a process for producing a charge retention medium, with which a coating film (precursor of a charge retention medium) containing a fluorinated copolymer having repeating units based on tetrafluoroethylene and repeating units based on ethylene can easily be formed on the surface of a substrate, even in a case where the surface of the substrate has a complicated shape. A process for producing a charge retention medium (electret), which comprises a step of applying a coating composition containing a fluorinated copolymer (A) having repeating units based on tetrafluoroethylene and repeating units based on ethylene, and an organic solvent (C), to a substrate (first substrate) to form a coating film.

Process for producing charge retention medium

To provide a composition comprising a fluorocopolymer such as an ethylene/tetrafluoroethylene copolymer which can be produced at a relatively low temperature, and its production process. A fluorocopolymer composition which comprises a fluorocopolymer such as an ethylene/tetrafluoroethylene copolymer and a fluorinated aromatic compound having a melting point of at most 230&#xb0; C. and having a fluorine content in the compound of from 5 to 75 mass %, and is in a solution state at a temperature of at most the melting point of the fluorocopolymer, and a process for producing the fluorocopolymer composition, which comprises a step of dissolving the fluorocopolymer in a solvent containing the fluorinated aromatic compound at a temperature of at most the melting point of the fluorocopolymer.

Fluorocopolymer composition and its production process

To provide a method for producing an organic compound having a sulfo group by efficiently hydrolyzing an organic compound having a fluorosulfonyl group with a small number of steps with a small quantity of waste liquid. A method for producing an organic compound having a sulfo group, which comprises bringing an organic compound having a fluorosulfonyl group into contact with subcritical water at from 200 to 320&#xb0; C. to convert the fluorosulfonyl group into a sulfo group.

Method for producing organic compound having sulfo group, method for producing liquid composition, and method for hydrolyzing organic compound having fluorosulfonyl group

To provide an acceleration sensor and a sensor network system having a construction in which the consumption of power to be consumed can be reduced and the sensor itself can be miniaturized without using any piezoelectric sensor or piezoelectric bimorph. An acceleration sensor device provided with an acceleration sensor which is an electrostatic induction conversion device for conversion between electric energy and kinetic energy, which comprises a conductor and an electret moving relatively to the conductor, said acceleration sensor device having: an acceleration detection unit to detect a signal corresponding to acceleration, from an AC voltage output by the acceleration sensor; a rectification unit to rectify the AC voltage; and a power supply circuit having a battery to power circuits in the device to work, to charge the battery with the rectified voltage as electric energy.

Acceleration sensor device and sensor network system

To provide a lecithinized superoxide dismutase (PC-SOD) composition useful as a drug material and a process for its production. The PC-SOD composition contains a PC-SOD obtained by substituting at least amino group in a specific SOD with a lecithin moiety represented by the following formula (I), wherein the PC-SOD contains a PC-SOD (A) having an m number of amino groups substituted with the lecithin moieties (wherein m is an integer of from 1 to 4 and averages from 1.5 to 2.4 as a main component and the PC-SOD (A) consists of a PC-SOD (a1) wherein m=1, a PC-SOD (a2) wherein m=2, a PC-SOD (a3) wherein m=3 and a PC-SOD (a4) wherein m=4. 

Lecithinized superoxide dismutase composition and a process for its production

To provide a novel fluoroadamantane derivative, a novel polymerizable fluoroadamantane derivative and a novel fluoropolymer, and processes for production thereof. To provide the following compound (3), the following compound (4), a polymer obtained by polymerizing the compound (4) and processes for production thereof: provided that Q represents &#x2014;CHF&#x2014; or &#x2014;CF&#x2014; (provided that six Qs may be the same or different), Z represents &#x2014;H, &#x2014;F or &#x2014;CHOH (provided that three Zs may be the same or different), W represents &#x2014;H or a Chydrocarbon group, R represents &#x2014;H, &#x2014;F, &#x2014;CHor &#x2014;CF, and J represents &#x2014;H, &#x2014;F, &#x2014;CHWOH or &#x2014;CHWOCOCR&#x2550;CH(provided that three Js may be the same or different).

Fluoroadamantane derivative, fluorine-containing polymer and production method

The present invention provides processes for producing a (4E)-5-chloro-2-isopropyl-4-pentenoate and an optical isomer of the (4E)-5-chloro-2-isopropyl-4-pentenoate, namely a process for producing a (4E)-5-chloro-2-isopropyl-4-pentenoate represented by the following formula (4), which comprises reacting a compound represented by the following formula (2) in the presence of an aprotic solvent (II) with a base (II) and then with (1E)-1,3-dichloro-1-propene to give a compound represented by the following formula (3), and dealkoxycarbonylating either ester in the compound represented by the following formula (3), and a process for producing a (S)-(4E)-5-chloro-2-isopropyl-4-pentenoate represented by the following formula (5), which comprises optically resolving a (4E)-5-chloro-2-isopropyl-4-pentenoate represented by the formula (4) obtained by the above-mentioned process (wherein R is a lower alkyl group or an aralkyl group). 

Process for producing (4E)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof

An alkene (1) is added to cyclopentenone (2) under the action of an alkyl lithium and an organic copper reagent to form an adduct, said adduct is reacted with e.g. a carboxylic anhydride (4) to obtain a prostaglandin derivative (6), which is then treated with a nitrogen-containing compound such as 2,2&prime;-bipyridyl to efficiently remove the organic copper reagent used in the synthesis and by-products derived from said reagent, to obtain a purified prostaglandin derivative (6) having a high purity:

Process for producing a purified prostaglandin derivative

A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.

Difluoroprostaglandin derivatives and their use

2-Arylquinolines represented by formula (1): ##STR1## wherein R.sup.1, R.sup.3 to R.sup.9 each represents hydrogen, halogen, lower alkyl, cyclic lower alkyl, aryl, aralkyl, alkoxy or --C.sub.m F.sub.2m+1 ; R.sup.2 represents hydrogen, halogen, lower alkyl, cyclic lower alkyl, aryl, aralkyl, alkoxy, --C.sub.n F.sub.2n+1 or --CH.sub.2 Q, in which Q represents a monovalent organic group obtained by eliminating from an organic compound having --NH-- the hydrogen atom bonded to the nitrogen, or halogen; X represents halogen or hydrogen; Y represents nitro or amino which may be protected with a protecting group; and m and n each represents an integer of from 1 to 6; and processes for producing the 2-arylquinolines.

2-arylquinolines and process for producing the same

Quinolin-2-yl benzoic acid compounds which are useful as intermediates of quinoline compounds having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds in which a carboxyl group bonded to a phenyl group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction.

Process for producing 2-(carboxyphenyl)-4-quinolinecarboxylic acid

A difluoroprostacyclin of the following formula (V), its lower alkanol ester or its pharmaceutically acceptable salt: ##STR1## wherein A is an ethylene group, a vinylene group or an ethynylene group, R is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryloxy group, Q is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group.

Difluoroprostacyclins

A quinoline compound represented by the formula (1) or a salt thereof: ##STR1## wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.

Quinoline compounds

Intermediates for difluoroprostacyclins and methods for their production

Growing community of inventors

Yokohama, Japan

Yoshitomi Morizawa